Durable medical equipment denials at external review

• rising

  It has risen over the published record: 14.3% in 2002 against 55.8% in 2025. What drove that is not in this data — the file holds outcomes, not who chose to appeal or how plans changed their own review.

• most-cited standard

  Reviewers named FDA more than any other standard here — 38 decisions, which came out at 78.9%, 23 points above the class as a whole. Citing a standard and the outcome share a cause; this is not the effect of naming it.

• high volume

  With 679 decisions in 2021-2025, this is among the five most-disputed treatment classes in the published record — one of the few where the numbers are stable enough to read year by year.

California requires each published decision to carry “a detailed case summary that includes the specific standards, criteria, and medical and scientific evidence, if any, that led to the case decision” (Health & Safety Code § 1374.33(h)(1)(K)). These are the elements our extraction found in this class, split by how the decision came out.

Read as description, not instruction. These are patterns in what reviewers wrote, not steps to follow, and no combination of them predicts an outcome. Only codes that cleared the validation gate appear — thirteen did not.

• FDA78.9%38
• American Diabetes Association—18
• American Heart Association—18
• American College of Cardiology—16
• American Urological Association—3
• American Academy of Neurology—2
• American Academy of Pediatrics—2
• Medicare / CMS—2

A rate here is the outcome of decisions that named the authority, not the effect of naming it. Reviewers cite the standard they applied; the citation and the outcome share a cause.

• Orthopedic & musculoskeletal25.9%116
• CNS & neuromuscular51.4%111
• Endocrine & metabolic67.9%106
• Cardiac & circulatory53.5%86
• Autism spectrum70.3%64
• Foot73.8%42
• Respiratory—28
• Genetic disease—27

Browse all condition classes · Pick your own pair

• Diabetes70.7%92
• Other54.8%84
• Autistic Disorder71.2%59
• Paralysis32.4%34
• Apnea/Sleep Apnea—25
• Cerebral Palsy—19
• Lymphedema—18
• Amputation—16

• Medical Necessity56.1%533
• Experimental/Investigational55.5%146

Medical-necessity review asks whether the care is needed. Experimental/investigational review asks whether it is likely to be more beneficial than standard therapy — a harder statutory test, and the rates show it.